ARMC8 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the A-549 human lung adenocarcinoma cell line. Through CRISPR/Cas9-mediated gene disruption, the ARMC8 gene encoding a critical subunit of the CTLH E3 ubiquitin ligase complex is functionally inactivated, establishing a loss-of-function model for investigating the ubiquitin-proteasome system in cancer biology. This polyclonal population preserves genetic heterogeneity while enabling robust analysis of ARMC8-dependent processes within a relevant epithelial tumor background.
The host A-549 cell line was originally derived from a 58-year-old Caucasian male with lung adenocarcinoma and serves as a widely employed model for type II alveolar epithelium. These adherent epithelial cells exhibit characteristics of advanced lung adenocarcinoma, including aberrant growth factor signaling and altered cell cycle regulation, making them particularly suitable for dissecting oncogenic pathways. A-549 cells are extensively utilized in respiratory disease research, drug development, and studies of tumor cell migration and invasion.
ARMC8 encodes a subunit of the CTLH (C-terminal to LisH) E3 ubiquitin ligase complex, which catalyzes ubiquitin transfer to substrate proteins, marking them for proteasomal degradation. The CTLH complex includes core components MAEA (GID9), WDR26 (GID7), RANBP9 (GID8), and RMND5A (GID2). ARMC8??s activity is influenced by upstream regulators such as growth factors (EGF, TGF-??), glucose availability, and AMPK signaling. Its downstream targets include cell cycle regulators cyclin D1 and CDK4, the oncoprotein c-MYC, and various metabolic enzymes, placing ARMC8 at the nexus of proliferation and metabolic control. Disruption of ARMC8 impairs CTLH complex assembly and function, leading to accumulation of these substrates and consequent alterations in cell cycle progression, metabolism, and survival.
In the context of A-549 lung adenocarcinoma cells, ARMC8 knockout provides a powerful system to dissect the role of CTLH-mediated ubiquitination in tumorigenesis. ARMC8 has been implicated in cell proliferation, migration, and tumor progression across multiple cancers, including lung adenocarcinoma, hepatocellular carcinoma, and breast cancer. Loss of ARMC8 function in this model may reveal dependencies on the ubiquitin-proteasome system and identify potential vulnerabilities for therapeutic intervention. The epithelial nature of A-549 cells further enables studies of ARMC8 in epithelial-mesenchymal transition and invasive behavior.
Typical applications include investigating CTLH complex assembly via co-immunoprecipitation, assessing ubiquitination dynamics through ubiquitination assays, and profiling substrate changes by mass spectrometry and western blotting. Functional studies such as cell viability (MTT), migration/invasion assays, and flow cytometry for cell cycle analysis can be employed to evaluate phenotypic consequences of ARMC8 loss. Transcriptomic analysis via RNA-seq allows exploration of downstream gene expression networks. This knockout model is an invaluable tool for drug target discovery and mechanistic studies in lung adenocarcinoma. For additional technical details, customized services, or ordering information, please contact Ascent Research.
